iRadimed price target raised to $100 from $75 at Lake Street

Lake Street raised the firm’s price target on iRadimed (IRMD) to $100 from $75 and keeps a Buy rating on the shares after a top and bottom line beat with revenue and EPS guidance increased in Q3. While acknowledging that shares trade at a premium valuation, the firm sees a record backlog providing near-term visibility and the new 3870 IV Pump launch driving growth acceleration in 2026, the analyst tells investors.